680 related articles for article (PubMed ID: 24849467)
21. Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma.
Godin C; Bodeau S; Saidak Z; Louandre C; François C; Barbare JC; Coriat R; Galmiche A; Sauzay C
Oncol Rep; 2019 Mar; 41(3):2041-2050. PubMed ID: 30569112
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
23. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42.
Wang R; Zhao N; Li S; Fang JH; Chen MX; Yang J; Jia WH; Yuan Y; Zhuang SM
Hepatology; 2013 Aug; 58(2):642-53. PubMed ID: 23468064
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.
Fernando J; Sancho P; Fernández-Rodriguez CM; Lledó JL; Caja L; Campbell JS; Fausto N; Fabregat I
J Cell Physiol; 2012 Apr; 227(4):1319-25. PubMed ID: 21604268
[TBL] [Abstract][Full Text] [Related]
26. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.
Peng H; Zhang Q; Li J; Zhang N; Hua Y; Xu L; Deng Y; Lai J; Peng Z; Peng B; Chen M; Peng S; Kuang M
Oncotarget; 2016 Mar; 7(13):17220-9. PubMed ID: 26967384
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.
Godin C; Louandre C; Bodeau S; Diouf M; Saidak Z; Conte MA; Chauffert B; Barbare JC; Barget N; Trinchet JC; Ganne N; Galmiche A
Anticancer Res; 2015 Mar; 35(3):1803-8. PubMed ID: 25750346
[TBL] [Abstract][Full Text] [Related]
28. Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
Dig Dis; 2014; 32(6):733-9. PubMed ID: 25376291
[TBL] [Abstract][Full Text] [Related]
29. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
30. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM
Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144
[TBL] [Abstract][Full Text] [Related]
31. Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
Erös de Bethlenfalva-Hora C; Mertens JC; Piguet AC; Kettenbach J; Schmitt J; Terracciano L; Weimann R; Dufour JF; Geier A
Clin Sci (Lond); 2014 Feb; 126(3):243-52. PubMed ID: 23822114
[TBL] [Abstract][Full Text] [Related]
32. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
Tsuchiya K; Asahina Y; Matsuda S; Muraoka M; Nakata T; Suzuki Y; Tamaki N; Yasui Y; Suzuki S; Hosokawa T; Nishimura T; Ueda K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Izumi N
Cancer; 2014 Jan; 120(2):229-37. PubMed ID: 24122122
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
34. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
Lo J; Lau EY; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
Hepatology; 2015 Aug; 62(2):534-45. PubMed ID: 25902734
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase.
Yan J; Tan C; Gu F; Jiang J; Xu M; Huang X; Dai Z; Wang Z; Fan J; Zhou J
Liver Transpl; 2013 May; 19(5):507-20. PubMed ID: 23408515
[TBL] [Abstract][Full Text] [Related]
36. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
Cao G; Li X; Qin C; Li J
Med Sci Monit; 2015 Oct; 21():3144-51. PubMed ID: 26476711
[TBL] [Abstract][Full Text] [Related]
38. Iron depletion enhances the effect of sorafenib in hepatocarcinoma.
Urano S; Ohara T; Noma K; Katsube R; Ninomiya T; Tomono Y; Tazawa H; Kagawa S; Shirakawa Y; Kimura F; Nouso K; Matsukawa A; Yamamoto K; Fujiwara T
Cancer Biol Ther; 2016 Jun; 17(6):648-56. PubMed ID: 27089255
[TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo.
Xu M; Xie XH; Xie XY; Xu ZF; Liu GJ; Zheng YL; Huang GL; Wang W; Zheng SG; Lü MD
Acta Radiol; 2013 Mar; 54(2):199-204. PubMed ID: 23171528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
